[HTML][HTML] A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain
G Irving, J Pénzes, B Ramjattan, M Cousins, R Rauck… - The Journal of …, 2011 - Elsevier
The balance between the pain relief provided by opioid analgesics and the side effects
caused by such agents is of particular significance to patients who take opioids for the long-
term relief of non-cancer pain. The spectrum of signs and symptoms affecting the
gastrointestinal (GI) tract associated with opioid use is known as opioid-induced bowel
dysfunction. Alvimopan is an orally administered, systemically available, peripherally acting
mu-opioid receptor (PAM-OR) antagonist, approved in the US for the management of …
caused by such agents is of particular significance to patients who take opioids for the long-
term relief of non-cancer pain. The spectrum of signs and symptoms affecting the
gastrointestinal (GI) tract associated with opioid use is known as opioid-induced bowel
dysfunction. Alvimopan is an orally administered, systemically available, peripherally acting
mu-opioid receptor (PAM-OR) antagonist, approved in the US for the management of …
